Investor mix
7 investors on record; lead investors include Kleiner Perkins; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 57% |
| Private equity | 1 | 14% |
| Other / undisclosed | 2 | 29% |
Developer of CAR T-cell-based immunotherapies for cancer and other devastating diseases
7 investors on record; lead investors include Kleiner Perkins; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 57% |
| Private equity | 1 | 14% |
| Other / undisclosed | 2 | 29% |